MiMedx Group (MDXG) Set to Announce Quarterly Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) is set to issue its quarterly earnings data after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of $0.05 per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.08. The company had revenue of $87.21 million during the quarter, compared to analysts’ expectations of $88.44 million. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG opened at $5.86 on Tuesday. The business’s 50-day simple moving average is $6.08 and its 200-day simple moving average is $6.67. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.22 and a current ratio of 3.85. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $9.27. The firm has a market cap of $864.96 million, a price-to-earnings ratio of 13.32 and a beta of 1.97.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price objective on shares of MiMedx Group in a research note on Thursday, August 1st. StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 15th. Finally, Craig Hallum dropped their price objective on MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $12.00.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.